When interim results from the PRIME study of aducanumab for Alzheimer’s disease were recently published in Nature, buzz about the study in the consumer media was instant — and sometimes hyperbolic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Despite the encouraging findings that this monoclonal antibody reduced amyloid-beta plaques in a dose-dependent fashion, it’s important to remind excited patients and families of the study’s relatively preliminary nature. Despite its inclusion of 165 patients and its randomized, placebo-controlled design, the PRIME study was still a phase 1b trial.
Confirmation of its findings is being sought in ongoing phase 3 trials, and Cleveland Clinic Lou Ruvo Center for Brain Health is a participating center. In this video, one of the Cleveland Clinic neurologists involved in phase 3 testing of aducanumab — James Leverenz, MD — shares perspectives on the PRIME findings, what they mean for the amyloid hypothesis, and the road ahead for aducanumab.